Soluble Urokinase Plasminogen Activator Receptor (SuPAR) Analysis for Diagnosis of Periprosthetic Joint Infection

被引:0
|
作者
Klim, Sebastian M. [1 ]
Prattes, Juergen [2 ]
Amerstorfer, Florian [1 ]
Niedrist, Tobias [3 ]
Zurl, Christoph [2 ]
Stradner, Martin [4 ]
Dreo, Barbara [4 ]
Glehr, Gunther [5 ]
Leithner, Andreas [1 ]
Glehr, Mathias [1 ]
Reinbacher, Patrick [1 ]
Sadoghi, Patrick [1 ]
Hauer, Georg [1 ]
机构
[1] Med Univ Graz, Dept Orthopaed & Trauma, A-8036 Graz, Austria
[2] Med Univ Graz, Dept Internal Med, Div Infect Dis, A-8036 Graz, Austria
[3] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, A-8036 Graz, Austria
[4] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, A-8036 Graz, Austria
[5] Univ Hosp Regensburg, Dept Surg, D-93053 Regensburg, Germany
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 02期
关键词
suPAR; joint infection; synovia; inflammation; diagnostic biomarker; PLASMA; INFLAMMATION; ARTHRITIS; BIOMARKER; SEPSIS; LEVEL;
D O I
10.3390/antibiotics13020179
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Soluble urokinase plasminogen activator receptors (suPARs) are a biomarker for inflammatory diseases. This study aims to investigate its diagnostic properties regarding periprosthetic joint infections (PJI). This retrospective cohort study included adult patients who underwent joint puncture for suspected PJI. The presence of PJI was determined according to the criteria of the European Bone and Joint Infection Society (EBJIS). Laboratory study analyses included the determination of white blood cells (WBC) in whole blood, C-reactive protein (CRP) in blood plasma, and suPAR in both blood plasma and synovial fluid. Appropriate diagnostic cut-off values were identified utilizing Youden's J, and their diagnostic performance was determined by calculating the positive (PPV) and negative predictive value (NPV) for each marker. Sixty-seven cases were included in the final analysis. Forty-three samples (64%) were identified as periprosthetic joint infection (PJI) and twenty-four specimen (36%) were PJI negative cases. The PPV and NPV were 0.80 and 0.70 for synovial suPAR, 0.86 and 0.55 for CRP, 0.84 and 0.31 for WBC and 1.00 and 0.31 for plasma suPAR. Synovial suPAR showed a solid diagnostic performance in this study and has the potential to be an alternative or complementary biomarker for PJI. Further investigations in larger patient collectives are indicated.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Effects of Acute Exercise and Allopurinol Administration on Soluble Urokinase Plasminogen Activator Receptor (suPAR)
    Sanchis-Gomar, Fabian
    Bonaguri, Chiara
    Pareja-Galeano, Helios
    Carmen Gomez-Cabrera, Mari
    Candel, Jorge
    Vina, Jose
    Lippi, Giuseppe
    CLINICAL LABORATORY, 2013, 59 (1-2) : 207 - 210
  • [32] Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients
    Lippi, Giuseppe
    Henry, Brandon M.
    Favaloro, Emmanuel J.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2021, 59 (11) : E413 - E415
  • [33] The value of urinary soluble urokinase plasminogen activator receptor (suPAR) in children with nephrotic syndrome
    Phuong Anh Le Thy
    Kiem Hao Tran
    Thuy Yen Hoang Thi
    Minh Phuong Phan Thi
    Huu Son Nguyen
    AIMS MEDICAL SCIENCE, 2021, 8 (02): : 163 - 174
  • [34] Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia
    T. Mölkänen
    E. Ruotsalainen
    C. W. Thorball
    A. Järvinen
    European Journal of Clinical Microbiology & Infectious Diseases, 2011, 30 : 1417 - 1424
  • [35] Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease
    Kolho, Kaija-Leena
    Valtonen, Elsa
    Rintamaki, Hanne
    Savilahti, Erkki
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2012, 47 (8-9) : 951 - 955
  • [36] Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism
    Joyce, Jessica
    Cabanas, Noel
    Pisharody, Rohan
    Ouyang, Bichun
    Patel, Roshni
    Reiser, Jochen
    Hall, Deborah A.
    Witek, Natalie
    PARKINSONISM & RELATED DISORDERS, 2022, 101 : 39 - 42
  • [37] Soluble urokinase Plasminogen Activator Receptor (suPAR) serum levels are elevated in patients with neuroendocrine neoplasia
    Burcin, Oe
    Mohr, R.
    Jann, H.
    Geisler, L.
    Tacke, F.
    Wiedenmann, B.
    Roderburg, C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 96 - 96
  • [38] Soluble urokinase plasminogen activator receptor (suPAR) for the prediction of ventilator-associated pneumonia (VAP)
    van Oort, Pouline M. P.
    Bos, Lieuwe D.
    Povoa, Pedro
    Ramirez, Paula
    Torres, Antonio
    Artigas, Antonio
    Schultz, Marcus J.
    Martin-Loeches, Ignacio
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [39] Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia
    Molkanen, T.
    Ruotsalainen, E.
    Thorball, C. W.
    Jarvinen, A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2011, 30 (11) : 1417 - 1424
  • [40] Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals
    Chew-Harris, Janice
    Appleby, Sarah
    Richards, A. Mark
    Troughton, Richard W.
    Pemberton, Christopher J.
    CLINICAL BIOCHEMISTRY, 2019, 69 : 36 - 44